981P - European Treatment and Outcome Study (EUTOS) score predicts early molecular response to imatinib therapy in chronic phase chronic myeloid leukemia...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Leukaemia
Personalised Medicine
Presenter Kataru Sudheer Reddy
Citation Annals of Oncology (2014) 25 (suppl_4): iv327-iv339. 10.1093/annonc/mdu339
Authors K. Sudheer Reddy1, M. Manickavasagam1, V. Venkata Sampath2, D. Barghavi1, A. Vindhyavasini1, A. Pai1, R.G. Balambika1
  • 1Medical Oncology, sri venkateswara institute of medical sciences, 517507 - Tirupati/IN
  • 2Medical Oncology, Sri Venkateswara Institute of Medical Sciences, 517507 - Tirupati/IN

Abstract

Aim

The aim of the present study is to assess the predictors of early molecular response in imatinib treated CP-CML patients.

Methods

The present study is a prospective, single arm, non randomized, observational study. Between June 2012 and December 2013, 68 adult patients with newly diagnosed CP-CML received imatinib 400mg/daily.BCR-ABL transcripts were measured in peripheral blood at 3rd month using quantitative RT-PCR. Results were expressed as BCR-ABL/ABL ratio. Early molecular response (EMR) was defined as a transcript level ≤ 10%. Univariate and multivariate analysis (Linear regression) was performed to identify potential factors associated with the achievement of EMR.Univariate analysis (Linear regression) with RQPCR value at 3rd month as dependent variable in relation to the other continuous variables was performed. Variables showing statistically significant association with the outcome (EMR at 3rd month) at p < 0.05 were considered as candidate variables for inclusion in the multivariate model. Multivariate analysis (linear regression) was performed with the potential candidate variables as the co-variates. SPSS software version 17.0 was used for analysis.

Results

The study population included 68 newly diagnosed patients of CP-CML, of which 55.88% (38) were males. The median age at diagnosis in our cohort was 46 years.According to Sokal risk stratification 55.88% (38), 33.82% (23) and10.29% (07) were in high, intermediate and low risk respectively. As per Hasford risk stratification score 25% (17), 61.76% (42), and 13.24% (09) were in high,intermediate and low risk respectively. EUTOS score stratified 58.82% (40) of patients as high risk and 41.18% (28) as low risk. 69.12% (47) of patients had b3a2 transcript and 30.88% (21) had b2a2 transcripts. 32.35% (22) achieved EMR at 3rd month. In univariate analysis, spleen size(p= <0.001),pretreatment basophil percentage(p= <0.001),WBC count at 3rd month(p = 0.006),percentage of Ph+ metaphases at 3rd month(p = 0.009) and EUTOS score (p = < 0.001) significantly predicted the achievement of EMR. In multivariate analysis spleen size(p = 0.01), pretreatment basophil percentage(p = < 0.001) and EUTOS score (p = < 0.001) significantly predicted the achievement of EMR.

Conclusions

EUTOS score at diagnosis predicts early molecular response to imatinib therapy at 3rd month.

Disclosure

All authors have declared no conflicts of interest.